The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 75 | 17.5x | 20.8x | Top tier | |
Growth | 37 | 1.8% | 6.1% | Bottom tier | |
Quality | 93 | 16.8% | 6.6% | Top tier | |
Safety | 59 | 2.6x | 0.7x | Around median | |
Capital Return | 83 | 4.03% | 2.02% | Top tier | |
Momentum | 80 | 21.0% | 4.1% | Top tier | |
Sentiment | 70 | 17 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Bristol-Myers Squibb Company, known by its ticker BMY on the New York Stock Exchange, is one of the world's largest biopharmaceutical companies focused on discovering, developing, and manufacturing innovative therapies for serious and intractable diseases. The company specializes in key therapeutic areas including oncology, cardiovascular diseases, immunology, and neuroscience, generating its revenues primarily from selling its innovative medicines to distributors, hospitals, and pharmacies globally, with an increasing focus on its innovative growth portfolio which includes advanced cellular and genetic therapies.
During the first quarter of 2026, the company recorded solid financial results, with total revenues reaching approximately $11.5 billion, representing a 1% growth compared to the same quarter of the previous year. According to EDGAR data, the company achieved a gross profit of $8.1 billion and a net income of $2.7 billion, with earnings per share reaching $1.31. The gross profit margin was negatively impacted, declining by 280 basis points to reach 70.3% due to changes in the product mix, while growth portfolio sales increased by 9% to reach $6.2 billion, supported by strong demand for new products.
Bristol-Myers Squibb's stock is currently trading within a 52-week range of $42.52 to $62.89, placing it below the average analyst price target of $62.6. The current analyst consensus reflects a Neutral recommendation on the stock, with a variance in estimates where the high target reaches $75 while the low target drops to $40, indicating a wait-and-see stance pending critical clinical trial results by the end of the year.
Figures in the text are as of 2026-06-18; the live price is shown at the top of the page.
In the first quarter of 2026, the company achieved total revenues of $11.5 billion, recording a 1% growth compared to the previous year. According to EDGAR data, net income for the first quarter was $2.7 billion and gross profit was $8.1 billion, with earnings per share of $1.31. The growth portfolio led this performance with a 9% increase in sales to reach $6.2 billion, helping to offset declining sales of some legacy drugs.
Eliquis recorded a strong performance with revenues of $4.1 billion in the first quarter of 2026, marking a 13% growth despite the impact of US price discounts that led to a temporary inventory build-up at wholesalers. In contrast, Opdivo revenues decreased by 8% to reach approximately $2.1 billion, a decline mainly attributed to inventory destocking among distributors in the US market. The company expects Opdivo inventory levels to stabilize and Eliquis pricing impacts to reverse positively in the upcoming periods of the year.
The company announced the US FDA's acceptance of the filing for iberdomide for the treatment of multiple myeloma, setting a PDUFA date of August 17, and granting it breakthrough therapy designation and priority review. Additionally, mezigdomide showed promising clinical results in the Phase 3 SUCCESSR-II study, contributing to a 52% reduction in leukemia risk in a pivotal trial. The company plans to present this detailed data at the ASCO conference and prepare regulatory filings to obtain the necessary approvals soon.
Automated analysis for informational purposes only — not investment advice.
Bristol-Myers Squibb is committed to achieving cost savings of $2 billion by the end of 2027 through its strategic productivity initiative. The company is utilizing artificial intelligence and automation technologies to accelerate research and development processes, aiming to speed up the identification of lead molecules by 50% and reduce development cycle times by 30%. These savings contribute to giving management the financial flexibility required to invest in business development deals and expand the product portfolio in its early and mid-stages.
Bristol-Myers Squibb maintained its cash dividend at $0.63 per share according to the announcement issued on June 17, 2026, confirming its commitment to rewarding shareholders. The company holds a strong financial position with approximately $11 billion in cash, cash equivalents, and marketable securities as of March 31. The company successfully generated operating cash flows of $1.1 billion during the first quarter, despite being temporarily affected by a $1.2 billion decrease in cash collections for Eliquis.